Fondaparinux overdosage: Difference between revisions

Jump to navigation Jump to search
(Created page with "__NOTOC__ {{Fondaparinux}} {{CMG}}; {{AE}} {{AZ}} ==Overdosage== *There is no known antidote for ARIXTRA. Overdose of ARIXTRA may lead to hemorrhagic complications. *'''Di...")
 
No edit summary
Line 4: Line 4:


==Overdosage==
==Overdosage==
*There is no known antidote for ARIXTRA. Overdose of ARIXTRA may lead to hemorrhagic complications.  
*There is no known antidote for ARIXTRA. Overdose of ARIXTRA may lead to hemorrhagic complications.  
*'''Discontinue treatment and initiate appropriate therapy if bleeding complications associated with overdosage occur'''.
*'''Discontinue treatment and initiate appropriate therapy if bleeding complications associated with overdosage occur'''.
 
*Data obtained in patients undergoing chronic intermittent hemodialysis suggest that clearance of ARIXTRA can increase by 20% during [[hemodialysis]].<ref name="dailymed.nlm.nih.gov">{{Cite web  | last =  | first =  | title = ARIXTRA (FONDAPARINUX SODIUM) INJECTION, SOLUTION [GLAXOSMITHKLINE LLC] | url =http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=05bb2dd4-5fb5-4ec9-29a8-d200e62d1a8f | publisher =  | date =  | accessdate =  }}</ref>
*Data obtained in patients undergoing chronic intermittent hemodialysis suggest that clearance of ARIXTRA can increase by 20% during [[hemodialysis]].


==References==
==References==

Revision as of 23:36, 5 February 2014

Fondaparinux
Arixtra® FDA Package Insert
Indications and Usage
Dosage and Administration
Dosage Forms and Strengths
Contraindications
Warnings and Precautions
Adverse Reactions
Drug Interactions
Use in Specific Populations
Overdosage
Description
Clinical Pharmacology
Nonclinical Toxicology
Clinical Studies
How Supplied/Storage and Handling
Patient Counseling Information
Labels and Packages
Clinical Trials on Fondaparinux
ClinicalTrials.gov

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Ahmed Zaghw, M.D. [2]

Overdosage

  • There is no known antidote for ARIXTRA. Overdose of ARIXTRA may lead to hemorrhagic complications.
  • Discontinue treatment and initiate appropriate therapy if bleeding complications associated with overdosage occur.
  • Data obtained in patients undergoing chronic intermittent hemodialysis suggest that clearance of ARIXTRA can increase by 20% during hemodialysis.[1]

References

  1. "ARIXTRA (FONDAPARINUX SODIUM) INJECTION, SOLUTION [GLAXOSMITHKLINE LLC]".

Adapted from the FDA Package Insert.